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Objective To evaluate whether cosmetically relevant dental effects occurred among children who had received
doxycycline for treatment of suspected Rocky Mountain spotted fever (RMSF).
Study design Children who lived on an American Indian reservation with high incidence of RMSF were classified
as exposed or unexposed to doxycycline, based on medical and pharmacy record abstraction. Licensed, trained
dentists examined each child’s teeth and evaluated visible staining patterns and enamel hypoplasia. Objective
tooth color was evaluated with a spectrophotometer.
Results Fifty-eight children who received an average of 1.8 courses of doxycycline before 8 years of age and who
now had exposed permanent teeth erupted were compared with 213 children who had never received doxycycline.
No tetracycline-like staining was observed in any of the exposed children’s teeth (0/58, 95% CI 0%-5%), and no
significant difference in tooth shade (P = .20) or hypoplasia (P = 1.0) was found between the 2 groups.
Conclusions This study failed to demonstrate dental staining, enamel hypoplasia, or tooth color differences
among children who received short-term courses of doxycycline at <8 years of age. Healthcare provider confidence
in use of doxycycline for suspected RMSF in children may be improved by modifying the drug’s label. (J Pediatr
2015;166:1246-51).
T
etracycline-class antibiotics (tetracyclines) once were used widely to treat a variety of infections in children, but studies
beginning in the 1950s showed a link between their use in young children and staining and enamel hypoplasia of devel-
oping teeth.1,2 Tetracyclines bind to calcium, which can lead to yellow, gray, and brown staining of developing teeth if
administered during tooth crown calcification, which most commonly occurs between birth and the age of 8 years for most
permanent teeth except third molars.3 Previous studies of children who received tetracyclines during odontogenesis showed
visible staining in 23%-92% (Table I).1,2,4-7 Because of these findings, the Food and Drug Administration requires that all
tetracyclines, including doxycycline, carry a label warning that the medication should not be used in children under the age
of 8 years because of concerns about dental staining, unless no other effective antibiotics exist.8
Doxycycline, a newer medication in the tetracycline class, has been available since 1967 and binds to calcium less readily than
other tetracyclines.9 There are no published studies linking doxycycline to dental staining when used at the dose and duration
recommended for treating rickettsial diseases. A study in 1969 reported possible faint staining of a single deciduous tooth in 1 of
25 pre-term infants treated with doxycycline; however, dose and duration were not provided, and the authors concluded stain-
ing was negligible compared to other tetracyclines.10 Several past studies have looked for evidence of visible dental staining in
children treated with doxycycline prior to the age of 8 years and found no evidence, even when multiple courses were admin-
istered.7,11 However, these studies examined small sample sizes of exposed patients, and employed subjective methods of tooth
shade evaluation that might be subject to interpretation bias.
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Table I. Studies examining dental staining because of treatment of children with tetracyclines
Reference Antibiotic (duration) Study population
Proportion (%) exposed
with stained teeth
Shwachman et al1 Chlortetracycline and oxytetracycline (long-term) Patients with cystic fibrosis 40/50 (80%)
Wallman and Hilton2 Tetracycline (short-term) Neonates 46/50 (92%)
Swallow et al4 Chlortetracycline, tetracycline,
and oxytetracycline (long-term)
Patients with cystic fibrosis 24/63 (38%)
Conchie et al5 Mixed tetracyclines (unknown duration) Children who had received tetracycline
prior to age of 6 and who are now 8-11 y
55/238 (23%)
Rebich et al6 Mixed tetracyclines (unknown duration) American Indian children 4-19 y 55/137 (40%)
Volovitz et al7 Doxycycline (short-term) Patients with asthma 0/31 (0%)
Vol. 166, No. 5  May 2015Early administration of doxycycline has been shown to be
the single most important factor influencing the survival of
patients with RMSF.15 Despite clear evidence that RMSF fa-
talities are preventable when treated early and appropriately,
and despite national AAP guidelines regarding treatment of
suspected RMSF in children, the case fatality rate for RMSF
infection among US children under the age of 10 years
currently is 5 times that of cases who are older.16 Only 35%
of US healthcare providers report using doxycycline to treat
suspected cases of RMSF in children <8 years of age, even
though 80% correctly identified doxycycline as the primary
treatment for adults and older children.17 Physician reluc-
tance to prescribe doxycycline to younger children may be
due to the dental staining legacy of older tetracyclines and
the current doxycycline label warning against use in children
<8 years of age.
RMSF recently has emerged as a significant public health
issue on tribal lands in eastern Arizona.15,18,19 Because of
intensive education efforts at one reservation’s Indian Health
Service (IHS) facility, healthcare providers there have
routinely prescribed doxycycline to all suspected RMSF cases,
regardless of age, since 2003.19 This practice has resulted in a
large population of children who have received 1 or more
courses of doxycycline prior to the age of 8 years. If pediatric
doxycycline administration causes adverse effects on teeth, it
should be detectable in this community, both visually and by
means of objective measurement.Methods
We performed a retrospective cohort study consisting of a re-
view of medical and pharmacy records and a cross-sectional
dental examination and questionnaire. Data on tetracycline-
like staining, enamel hypoplasia, and tooth shade were
collected during the dental examination. Potential tooth
darkening behaviors were captured through a questionnaire.
Any history of receiving doxycycline was established by a re-
view of medical and pharmacy records. The study was con-
ducted with the approval of the Tribal Council, and the
Centers for Disease Control and Prevention and the regional
IHS Institutional Review Boards. Letters were mailed to res-
ervations and additionally distributed through schools. Par-
ents/legal guardians of study subjects gave written informed
consent and children provided oral assent.The target population was all children between the ages of
8 and 16 years residing and attending schools on 1 American
Indian reservation in eastern Arizona. This target population
numbered approximately 2500 children, based on US Census
data.20 The study was conducted August-September, 2013.
Children aged 16 years at the time of the study would have
had at least 1 crown still calcifying in 2003 when physicians
first began using doxycycline in children for RMSF. A mini-
mum age of 8 years was used because at this age children typi-
cally have at least 1 permanent maxillary anterior tooth
erupted at time of examination.
All dental examinations were performed by licensed den-
tists, who were blinded to the exposure status of the chil-
dren. Prior to initiation of the study, 5 dentists who
would serve as dental examiners were trained by a single
experienced dentist in the recognition of the typical signs
of tetracycline dental staining, using a set of color photo-
graphs displaying nonstudy persons with and without
tetracycline-induced defects. Training also was provided
on the use and calibration of the VITA Easyshade Compact
instrument (Vita Zahnfabrik H. Rauter GmbH and Co, Bad
S€ackingen, Germany), a handheld spectrophotometer used
to evaluate the shade of teeth. The Easyshade provides 16
tooth shade measures, ranging from 1 to 16, where 1 is
considered the brightest shade and 16 the darkest.21 After
children brushed their teeth, a trained dentist performed a
visual examination of fully erupted permanent maxillary
central incisors, lateral incisors, cuspids, and first premo-
lars. Children without any of these teeth present were
excluded. Teeth with orthodontic brackets, restoration, or
reconstruction work which precluded examination of the
labial surface of the tooth were excluded. Dentists noted
the presence of decay, fluorosis, enamel hypoplasia, and
presence of any tetracycline-like staining patterns on the
labial aspect of these teeth. For tetracycline-like staining,
dentists looked for characteristic blue-gray coloration on
the enamel with a normal tooth structure, absence of
enamel pitting, and regular glossiness of enamel. Typical
tetracycline-associated lesions would have clear horizontal
borders and may affect any area of the tooth, from bands
to the entire surface. The dentist then utilized the VITA
Easyshade Compact spectrophotometer to obtain a single
reading of tooth shade from the upper-middle one-third
of the facial aspect of each of these same teeth.22 In addition
to the dental examination, children were asked how many1247
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dark colored beverages such as coffee, tea, or cola, and
how frequently they used tobacco products.
In order to obtain a complete medical history on each
child, parents were questioned regarding all healthcare facil-
ities where their child received medical care. Medical and
pharmacy records were obtained from the local IHS hospital.
Records from off-reservation primary care providers and ter-
tiary care centers were reviewed if applicable. Dose, duration,
and number of courses of all tetracyclines dispensed,
including doxycycline, were abstracted from each child’s
medical and pharmacy record. No other tetracyclines were
reported in any record. Following record abstraction, chil-
dren who had received at least 1 course of a tetracycline-
doxycycline were assigned to the exposed group. All others
were assigned to the unexposed group.
Statistical Analyses
Only those teeth presumed to still be calcifying at the time of
doxycycline administration were considered in our analysis
of the exposed group’s dental data, as follows: age 5 years
and younger, first premolar, cuspid, lateral incisor, and cen-
tral incisor still calcifying; age 6, first premolar and cuspid
still calcifying; and age 7, cuspid still calcifying.3 All other re-
maining dental data were excluded from analysis of the
exposed group. For the unexposed group, no dental data
were excluded from the analysis.
All statistical analyses were performed at a significance
level of a = 0.05. All computations were performed using
SAS v 9.3 (SAS Institute, Cary, North Carolina) except the
CI for a zero numerator proportion, calculated using the
rule of 3.23 Because it is at least as powerful as other unbiased
2-sided tests and because it is robust against violations of
normality, the 2-sample t test with equal variance was used
to compare pairs of means. The association between pairs
of categorical variables was tested using Pearson c2 test for
general association; except, when any expected frequency
was <5, Fisher exact test was used.
Because the mean age of children in the unexposed cohort
was higher than the exposed cohort (most likely influenced
by changes in clinical practice on the reservation beginning
in 2009, when increasing rates of RMSF prompted wider
treatment of patients and increasing the number of exposed
younger patients), the Breslow-Day test for homogeneity of
association was used to test for effect modification by age.
Mantel-Haenszel estimates of the common prevalence ratio
were used when adjusting for age.
Spearman correlation coefficient was used to test the as-
sociation of exposure as the total number of days of
receiving doxycycline before the age of 8 years, or simply
the duration of doxycycline, with 2 outcomes: (1) average
tooth shade; and (2) the proportion of teeth with enamel
hypoplasia. Spearman correlation coefficient ranges from
1 to 1, with values approaching 0 showing the least cor-
relation. To assess potential confounding by either age at
the time of study or the proportion of teeth with fluorosis,
Spearman correlation coefficient was used to test the1248pairwise association between these potential confounders
with the duration of doxycycline and both outcomes. Con-
trolling for potential confounders associated with the
duration of doxycycline or either outcome, Spearman par-
tial correlation coefficients were used to test the associa-
tion between the duration of doxycycline and both
outcomes.
Results
The records of 366 eligible children were reviewed. None had
ever received a tetracycline-class antibiotic other than doxy-
cycline. Of these, 335 children were present at school on the
day of the examination and assented to participate.
Of the 335 children examined, 76 received at least 1 dose of
doxycycline prior to the age of 8 years. However, only 58 chil-
dren received doxycycline during the period of calcification
of at least 1 tooth and had at least 1 of these exposed teeth
fully erupted at the time of the dental examination. These
58 children were considered the exposed group for our anal-
ysis. Eighteen children who received doxycycline before the
age of 8 without an erupted exposed tooth, and 46 children
who had first received doxycycline at 8 years old or older
were excluded from the analysis. The remaining 213 children
who never received doxycycline were considered the unex-
posed group in our analysis.
The 58 children in the exposed group received a total of 107
courses of doxycycline before the age of 8 years old. The average
duration of these courses of doxycycline was 7.3 days (range
1-10, SD = 2.8). The mean doxycycline dose was 2.3 mg/kg
(range 0.3-2.9, SD= 0.40), which is not dissimilar from the rec-
ommended dose of 2.2mg/kg/dose (maximum, 100mg/dose).
The average ageof doxycycline administrationwas 4.5 years old
(range 0.2-7.9, SD = 2.4). The route typically was oral (98%),
and the frequency typically was 2 doses daily (97%). Doxycy-
cline was administered according to a reservation-wide treat-
ment algorithm recommending the antibiotic be
administered to all patients presenting with fever $2 days, so
many of these 58 children receivedmultiple courses of doxycy-
cline prior to 8 years of age, for an average of 1.8 courses per
child.
The mean age at time of dental exam of those who received
doxycycline was 9.8 years old (range 8.1-15.6, SD = 1.7), and
the mean age of those who had not was 11.8 years old (range
8.0-16.9, SD = 2.2). The difference between the average age of
those who received doxycycline and those who did not was
2.1 years (SD = 2.1, P < .001). There was no significant differ-
ence between our 2 groups regarding whether they brushed
their teeth twice daily (P = .50), whether they drank any
dark-colored beverages (P = .36), or whether they used any
tobacco (P = .18); and, these results were qualitatively similar
after adjusting for age at exam (Table II).
Dental Examination
No visible tetracycline-like staining patterns were observed
on any of the teeth of the 335 children examined, including
those 58 children who received doxycycline before 8 yearsTodd et al
Table II. The prevalence of enamel hypoplasia, the prevalence of fluorosis, and dental hygiene habits by whether exposed
to doxycycline
Doxycycline
<8 y, N (%)
No doxycycline,
N (%)
Crude PR
(95% CI)
Crude PR,
P value
Breslow-Day,
P value
Age-adjusted
PR (95% CI)
Age-adjusted
PR, P value
Enamel hypoplasia 2 (4) 8 (4) 0.92 (0.2-4.2) 1.00 .79 1.6 (0.2-13.5) .65
Fluorosis 5 (9) 28 (13) 0.66 (0.3-1.6) .35 .54 0.86 (0.4-2.0) .72
Brushes $2 times daily 40 (75) 148 (71) 1.1 (0.9-1.3) .50 .32 1.1 (0.9-1.4) .34
Any dark drinks 41 (71) 163 (77) 0.9 (0.77-1.1) .36 .32 0.93 (0.8-1.1) .48
Tobacco use 2 (4) 21 (10) 0.4 (0.1-1.4) .18 .64 0.75 (0.2-3.1) .68
PR, prevalence ratio.
The crude PR and its 95% CI are presented, as well as the age-adjusted PR.
Results of the Breslow-Day test for the homogeneity of the associations are stratified by age as a whole number.
May 2015 ORIGINAL ARTICLESof age (95% CI 0%-5%). Enamel hypoplasia was observed in
10 children (4%), but exposure to doxycycline was not asso-
ciated with the presence of enamel hypoplasia (P = 1.0;
Table II). Similarly, fluorosis-like hypomineralization was
observed in 33 children (12%) but was not associated with
exposure to doxycycline (P = .35; Table II).
Children exposed to doxycycline prior to the age of
8 years had an average tooth shade of 9.5 (range 3.0-16,
SD = 2.5). Those never having received doxycycline had
an average tooth shade of 9.0 (range 2.1-15.0, SD = 2.3).
There was no significant difference in tooth shade between
the 2 groups (P = .20). The size of the groups allowed detec-
tion of a 1.0 difference in average tooth shade with a power
of 0.8, and a 1.3 tooth shade difference with a power of
0.95, assuming a SD of 2.5. No significant differences
were observed in the average tooth shade of children
when grouping by questionnaire responses or the presence
of dental defects (Table III).
Duration of doxycycline was not correlated with the pro-
portion of teeth with enamel hypoplasia (Spearman correla-
tion coefficient r = 0.001, P = .98) nor with the average
tooth shade (r = 0.07, P = .28). Those children who were
younger at the time of the dental examination were more
likely to have received a longer duration of doxycycline
(r = 0.39, P < .001). The proportion of teeth with fluo-
rosis was not correlated with duration of doxycyclineTable III. Mean tooth shade of children at dental
examination, grouped by exposure to doxycycline,
presence of enamel hypoplasia, presence of fluorosis,
and dental hygiene habits
N Mean tooth shade (SD) P value
Doxycycline before 8 y 58 9.5 (2.6) .20
No doxycycline 213 9.0 (2.5)
Any enamel hypoplasia 10 9.8 (3.1) .38
No enamel hypoplasia 261 9.1 (2.5)
Any fluorosis 33 9.7 (2.7) .16
No fluorosis 238 9.1 (2.5)
Brushes teeth $2 times daily 188 8.9 (2.6) .10
Brushes teeth <2 times daily 74 9.5 (2.3)
Any dark drinks* 204 9.1 (2.4) .98
No dark drinks* 67 9.1 (2.8)
Any tobacco* 23 9.1 (2.4) .86
No tobacco* 242 9.2 (2.6)
The SD and the P value from the 2-sample t test with equal variance are presented.
*Not all participants provided answers.
No Visible Dental Staining in Children Treated with Doxycycline f(r = 0.07, P = .27), with the proportion of teeth with
enamel hypoplasia (r = 0.07, P = .23), nor with the
average tooth shade (r = 0.08, P = .18). Controlling for
age at examination, the duration of doxycycline was not
correlated with the proportion of teeth with enamel hypo-
plasia (Spearman partial correlation coefficient q = 0.04,
P = .53) nor with the average tooth shade (q = 0.09,
P = .15; Figure).
Discussion
We found no evidence of cosmetically relevant dental stain-
ing of permanent teeth in 58 children who had received
doxycycline for treatment of RMSF prior to 8 years of
age. Furthermore, the study found no evidence of an
increased prevalence of enamel hypoplasia, and no evidence
of tooth shade difference, between exposed and unexposed
children. Moreover, there was no evidence that multiple
doxycycline courses resulted in dental effects, even when
children received 3 or more courses of doxycycline while
teeth were developing.
In a study of similar design and methodology, although
of smaller patient sample size, Volovitz et al used licensed
dentists to examine 31 children who had received a mean
number of 2.1 courses of doxycycline (4 mg/kg twice on
the first day, and then 2 mg/kg per day for 9 days,
10 day total course) for treatment of resistant asthma.7
The dentists also examined 30 children who had notFigure. A scatterplot of average tooth shade by age at ex-
amination, stratified by doxycycline exposure.
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and subjective evaluation of tooth color. Similar to our
findings, Volovitz et al found no evidence of dental stain-
ing in patients treated with doxycycline. When the data
regarding visible dental staining from our study are com-
bined with the findings from Volovitz et al, the conclu-
sions are even more compelling, with a combined dental
staining prevalence rate of 0% (0/89, 95% CI 0%-3%)
among children treated with doxycycline.7 In contrast, in
the published literature, dental staining was reported in
23%-92% of children treated with older tetracyclines
(Table I).1,2,4-6
This study is subject to several limitations. Only externally
visible dental effects (staining, tooth shade, and hypoplasia)
were evaluated, as these factors were believed to be the
most cosmetically relevant. Although most children received
care and had prescriptions dispensed at the IHS facility, it is
possible that parents did not recall all locations where a child
received care and that some children in the unexposed group
may have received doxycycline outside of our knowledge.
Although the prescribed dosage, duration, date of adminis-
tration, and quantity dispensed of doxycycline recorded in
the medical and pharmacy records were used in our analysis,
we could not confirm whether a child completed the entire
course of doxycycline prescribed to them. Children’s answers
to the questions on dental habits could be biased based on the
child’s ability to recall behaviors, to understand the question,
and to admit to unhealthy behavior. The wide range of tooth
shades seen among both exposed and unexposed children
suggests that objectively determined tooth shade can be high-
ly variable among individuals, and may not be a wholly reli-
able means of assessing tooth shade differences when
comparing individuals with individuals (Figure); however,
our comparison looked at average tooth shade between
groups, lessening the effect of individual variability. Finally,
although every effort was made to train dentists providing
examinations according to a single identification standard,
there may have been inter-rater variability in both visual
assessments and use of the spectrophotometer.
Administering short courses of doxycycline of 10 days or
less to children <8 years of age for treatment of RMSF
does not darken the shade of teeth, cause visible staining,
or increase the risk of enamel hypoplasia. Despite strong
AAP recommendations to treat suspected RMSF in children
with doxycycline, pediatric mortality because of RMSF re-
mains higher than adult mortality, and US healthcare pro-
viders report reluctance to prescribe doxycycline for
suspected RMSF in children.16,17 To improve healthcare pro-
vider confidence in their treatment choices and reduce pedi-
atric mortality due to RMSF, current doxycycline label
warnings about possible dental effects should be reconsid-
ered, especially given the cumulative lack of evidence for
dental staining. n
We are indebted to Israel Agaku, Susan Mongeau, Ella Oong, and
Mary Stitt for performing dental examinations; Holly Biggs, Jessica
Francies, Brent Hobbs, Julian Jolly, Susanna Schmink, Rob Sulzbach,
Candice Williams, and Patricia Yu for record abstraction and data1250collection; and Community Health Representatives for assistance
with recruitment of study participants and data collection.
Submitted for publication Dec 24, 2014; last revision received Jan 21, 2015;
accepted Feb 5, 2015.
Reprint requests: Jennifer H. McQuiston, DVM, MS, Centers for Disease
Control and Prevention, 1600 Clifton Rd, MS D-25, Atlanta, GA 30333. E-mail:
fzh7@cdc.govReferences
1. ShwachmanH, Fekete E, Kulczycki LL, Foley GE. The effect of long-term
antibiotic therapy in patients with cystic fibrosis of the pancreas. Anti-
biot Annu 1958;6:692-9.
2. Wallman IS, Hilton HB. Teeth pigmented by tetracycline. Lancet 1962;1:
827-9.
3. Logan WHG, Kronfeld R. Development of the human jaws and sur-
rounding structures from birth to the age of fifteen years. J Am Dental
Assoc 1933;20:379-427.
4. Swallow JN, De Haller J, Young WF. Side-effects to antibiotics in cystic
fibrosis: dental changes in relation to antibiotic administration. Arch Dis
Child 1967;42:311-8.
5. Conchie JM, Munroe JD, Anderson DO. The incidence of staining
of permanent teeth by the tetracyclines. Can Med Assoc J 1970;
103:351-6.
6. Rebich T, Kumar J, Brustman B. The St. Regis environmental
health issue: assessment of dental defects. J Am Dental Assoc
1983;106:630-3.
7. Volovitz B, Shkap R, Amir J, Calderon S, Varsano I, Nussinovitch M.
Absence of tooth staining with doxycycline treatment in young children.
Clin Pediatr 2007;46:121-6.
8. Doxycycline and penicillin procaine administration for inhalational
anthrax (post-exposure). In: Register Fed.02 November 2001:
55679-82.
9. Schach von Wittenau M. Some pharmacokinetic aspects of doxycycline
metabolism in man. Chemotherapy 1968;13(Suppl):50.
10. Forti G, Beniucori C. Doxycycline and the teeth. Lancet 1998;1:782.
11. Lochary ME, Lockhart PB, Williams WT. Doxycycline and staining of
permanent teeth. Pediatr Infect Dis J 1998;17:429-31.
12. Red Book: 2012 Report of the Committee on Infectious Diseases. Elk
Grove Village, IL: American Academy of Pediatrics; 2012.
13. Chapman AS, Tickborne Rickettsial Disease Working Group. Diag-
nosis and management of tickborne rickettsial diseases: Rocky Moun-
tain spotted fever, ehrlichiosis, and anaplasmosis–United States.
Centers for Disease Control and Prevention; 2006.
14. Holman RC, Paddock CD, Curns AT, Krebs JW, McQuiston JH,
Childs JE. Analysis of risk factors for fatal Rocky Mountain Spotted Fe-
ver: evidence for superiority of tetracyclines for therapy. J Infect Dis
2001;184:1437-44.
15. Regan J, Traeger M, Humphrey D, Mahoney D, Martinez M,
Emerson GL, et al. Risk factors for fatal outcome from Rocky Mountain
spotted fever in a highly endemic area: Arizona, 2002-2011. Clin Infect
Dis 2015. In press.
16. Dahlgren FS, Holman R, Paddock C, Callinan L, McQuiston J. Fatal
Rocky Mountain spotted fever in the United States, 1999-2007
[Erratum, Am J Trop Med Hyg 2013;89:816]. Am J Trop Med
Hyg 2012;86:713-9.
17. Zientek J, Dahlgren FS, McQuiston J, Regan J. Self-reported treatment
practices by healthcare providers could lead to death from RockyMoun-
tain spotted fever. J Pediatr 2014;164:416-8.
18. Demma L, Traeger M, Nicholson W, Paddock CD, Blau DM,
Eremeeva ME, et al. Rocky Mountain spotted fever from an unexpected
tick vector in Arizona. N Engl J Med 2005;353:587-94.
19. Traeger MS, Regan J, Humphrey D, Mahoney D, Martinze M, Emerson
GL, et al. Differentiation of Rocky Mountain spotted fever from similar
illness in a highly endemic area: Arizona, 2002-2011. In press.Todd et al
May 2015 ORIGINAL ARTICLES20. 2010 Census Summary File 1 [Arizona], http://2010.census.gov/
2010census/popmap/; 2011. Accessed 22 April, 2014.
21. VITA classical shade guide. Vident, http://vident.com/products/shade-
management/vita-classical-previously-the-lumin-vacuum-shade-guide/;
2014. Accessed March 21, 2014.No Visible Dental Staining in Children Treated with Doxycycline f22. VITA Easyshade Compact Operating Instructions, http://vident.
com/wp-content/uploads/2011/09/VITA-Easyshade-Compact-Instructi
ons-for-Use_1506E.pdf. Accessed April 17, 2014.
23. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all
right? Interpreting zero numerators. JAMA 1983;249:1743-5.or Suspected Rocky Mountain Spotted Fever 1251
